PRKAG1 and neoplasm: Results showed that the tumor size and volume in the Hepa1-6-shPRKAG1 group were significantly smaller than those in the Hepa1-6-shNC group, intuitively indicating that PRKAG1 knockdown could effectively inhibit the growth of HCC xenografts (Figures 12A, B).